LENZ THERAPEUTICS, INC. Impairment of Long-Lived Assets Held-for-use
LENZ THERAPEUTICS, INC. (LENZ) reported Impairment of Long-Lived Assets Held-for-use of $54.10 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2024-02-27
- LENZ THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2023 was $54.10M.
- LENZ THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
- LENZ THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
- LENZ THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2020 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2023-12-31 | $54.10M 10-K · filed 2024-02-27 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-27 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-20 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |